New Delhi: New Covid-19 subvariant BA.3.2, nicknamed “Cicada,” is spreading across the United States, drawing attention due to its 70-75 spike protein mutations, far more than the original Omicron strain. Despite its high mutation count, global health authorities maintain that the overall risk remains low. Cicada is a descendant of the BA.3 lineage last commonly seen in early 2022. While early data show no increase in severe disease, the subvariant’s extensive mutations could reduce antibody neutralisation from previous infections or vaccinations.
Scientists stress that current vaccines still provide strong protection against severe illness, hospitalisation, and death. The World Health Organisation classifies BA.3.2 as a Variant Under Monitoring, signalling close observation while continuing to urge vaccination, especially for high-risk populations.
Insights from experts on Covid 19 BA.3.2 Cicada variant
What Pulmonology’s Senior Consultant Dr Avi Kumar says?
- BA.3.2 causes primarily mild symptoms such as cold, cough, and fever, particularly in children.
- Current 2025-26 vaccines targeting JN.1 and LP.8.1 offer partial protection, but remain effective in preventing severe disease.
- Booster doses are recommended for stronger immunity, particularly among high-risk groups.
WHO guidance on Covid 19 BA.3.2 Cicada variant
- Vaccination continues to be the primary strategy to prevent hospitalisation and death.
- Standard precautions like masking in crowded places remain important.
- Early detection and monitoring are essential, especially in countries with emerging cases.
High-risk groups and safety measures
Elderly individuals, those with comorbidities, and frequent travellers are advised to stay updated on boosters. Personalised guidance from doctors should be sought when necessary. Though the risk in India is currently low, awareness and proactive measures are recommended.
Global spread and surveillance
BA.3.2 was first detected in South Africa in late 2024 and has since been reported in at least 23 countries. In the US, cases have been found in patients and wastewater in 29 states. Monitoring continues, with no evidence yet of a dominant global spread.
Covid-19 vaccination, vigilance, and basic hygiene measures remain the best tools against the evolving Cicada variant.